CytoSorbents Corporation $(CTSO)$ has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.